文献速递生殖医学母胎医学

高龄产妇通过极体微阵列分析进行非整倍体植入前遗传学检测:一项随机临床试验

Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial.
PubMed 文献 · Hum Reprod · 2018-01-01

这项跨国多中心随机临床试验纳入396例36-40岁计划行ICSI的女性,比较首极体和第二极体全面染色体筛查(CCS)选择胚胎与不筛查的ICSI。筛查组1年内活产50/205(24%),对照组45/191(24%),差异0.83%(95%CI:-7.60至9.18%);筛查组移植更少(RR=0.81,95%CI:0.74-0.89)、流产更少(RR=0.48,95%CI:0.26-0.90)。

要点

  • 36-40岁女性极体CCS选择胚胎未显著提高1年内活产率。
  • 筛查组移植率降低(RR=0.81),流产率降低(RR=0.48)。
  • 作者认为胚胎选择可减少干预且结局相当,但成本与实验室负担等利弊待明确。

核心结论

  • 通过首极体和第二极体CCS选择整倍体胚胎移植并未在36-40岁女性中实质性提高活产率。
  • 活产率相似的同时移植更少、冷冻保存更少且流产更少,作者认为这提示PGT-A可能有临床获益,可考虑用于减少干预数量同时获得相当结局。
  • 作者指出这些获益是否超过患者成本、IVF实验室更高工作量以及延长培养和/或冷冻保存对子代的潜在影响尚待证明。

研究设计与样本

  • 跨国、多中心、实用性随机临床试验,采用意向性治疗分析。
  • 2012年6月至2016年12月共纳入396例女性,205例分配至首极体和第二极体CCS组(研究组),191例分配至不进行染色体筛查的ICSI组(对照组)。
  • 采用区组随机化,按中心和年龄组分层;参与者和临床医生在入组时至干预次日设盲。
  • 纳入标准为女性伴侣36-40岁且计划行ICSI的不孕夫妇;主要排除标准为既往3次或以上IVF或ICSI失败、3次或以上临床流产、反应差或卵巢储备低。
  • 主要结局为干预开始后1年内记录的新鲜或冷冻胚胎移植后的累积活产率。

主要发现

  • 筛查组205例中50例(24%)在1年内经干预活产,对照组191例中45例(24%)活产,差异0.83%(95%CI:-7.60至9.18%)。
  • 筛查组移植人数显著更少(RR=0.81;95%CI:0.74-0.89)。
  • 筛查组流产人数显著更少(RR=0.48;95%CI:0.26-0.90)。
  • 筛查组32例结果全部为非整倍体的患者中仅11例接受了第二个治疗周期。

关键数值与推荐

  • 采用Illumina的24sure阵列对受精卵的首极体和第二极体进行阵列比较基因组杂交(aCGH)分析。
  • 若第一个治疗周期所有卵母细胞均为非整倍体,则提供第二个采用极体阵列CGH的治疗。

临床怎么用

  • 作者认为这种胚胎选择方式可考虑用于减少干预数量同时产生相当结局。
  • 作者指出其获益是否超过患者成本、IVF实验室更高工作量及延长培养和/或冷冻保存对子代的潜在影响尚待证明。

局限性

  • 由于招募不理想,未达到目标样本量;然而纳入样本允许90%把握度检测目标增幅。
  • 累积结局数据仅限于1年。
  • 筛查组32例结果全部为非整倍体的患者中仅11例接受了第二个治疗周期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does preimplantation genetic testing for aneuploidy (PGT-A) by comprehensive chromosome screening (CCS) of the first and second polar body to select embryos for transfer increase the likelihood of a live birth within 1 year in advanced maternal age women aged 36-40 years planning an ICSI cycle, compared to ICSI without chromosome analysis? SUMMARY ANSWER: PGT-A by CCS in the first and second polar body to select euploid embryos for transfer does not substantially increase the live birth rate in women aged 36-40 years. WHAT IS KNOWN ALREADY: PGT-A has been used widely to select embryos for transfer in ICSI treatment, with the aim of improving treatment effectiveness. Whether PGT-A improves ICSI outcomes and is beneficial to the patients has remained controversial. STUDY DESIGN, SIZE, DURATION: This is a multinational, multicentre, pragmatic, randomized clinical trial with intention-to-treat analysis. Of 396 women enroled between June 2012 and December 2016, 205 were allocated to CCS of the first and second polar body (study group) as part of their ICSI treatment cycle and 191 were allocated to ICSI treatment without chromosome screening (control group). Block randomization was performed stratified for centre and age group. Participants and clinicians were blinded at the time of enrolment until the day after intervention. PARTICIPANTS/MATERIALS, SETTING, METHODS: Infertile couples in which the female partner was 36-40 years old and who were scheduled to undergo ICSI treatment were eligible. In those assigned to PGT-A, array comparative genomic hybridization (aCGH) analysis of the first and second polar bodies of the fertilized oocytes was performed using the 24sure array of Illumina. If in the first treatment cycle all oocytes were aneuploid, a second treatment with PB array CGH was offered. Participants in the control arm were planned for ICSI without PGT-A. Main exclusion criteria were three or more previous unsuccessful IVF or ICSI cycles, three or more clinical miscarriages, poor response or low ovarian reserve. The primary outcome was the cumulative live birth rate after fresh or frozen embryo transfer recorded over 1 year after the start of the intervention. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 205 participants in the chromosome screening group, 50 (24%) had a live birth with intervention within 1 year, compared to 45 of the 191 in the group without intervention (24%), a difference of 0.83% (95% CI: -7.60 to 9.18%). There were significantly fewer participants in the chromosome screening group with a transfer (relative risk (RR) = 0.81; 95% CI: 0.74-0.89) and fewer with a miscarriage (RR = 0.48; 95% CI: 0.26-0.90). LIMITATIONS, REASONS FOR CAUTION: The targeted sample size was not reached because of suboptimal recruitment; however, the included sample allowed a 90% power to detect the targeted increase. Cumulative outcome data were limited to 1 year. Only 11 patients out of 32 with exclusively aneuploid results underwent a second treatment cycle in the chromosome screening group. WIDER IMPLICATIONS OF THE FINDINGS: The observation that the similarity in birth rates was achieved with fewer transfers, less cryopreservation and fewer miscarriages points to a clinical benefit of PGT-A, and this form of embryo selection may, therefore, be considered to minimize the number of interventions while producing comparable outcomes. Whether these benefits outweigh drawbacks such as the cost for the patient, the higher workload for the IVF lab and the potential effect on the children born after prolonged culture and/or cryopreservation remains to be shown. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the European Society of Human Reproduction and Embryology. Illumina provided microarrays and other consumables necessary for aCGH testing of polar bodies. M.B.'s institution (UZBrussel) has received educational grants from IBSA, Ferring, Organon, Schering-Plough, Merck and Merck Belgium. M.B. has received consultancy and speakers' fees from Organon, Serono Symposia and Merck. G.G. has received personal fees and non-financial support from MSD, Ferring, Merck-Serono, Finox, TEVA, IBSA, Glycotope, Abbott and Gedeon-Richter as well as personal fees from VitroLife, NMC Healthcare, ReprodWissen, BioSilu and ZIVA. W.V., C.S., P.M.B., V.G., G.A., M.D., T.E.G., L.G., G.Ka., G.Ko., J.L., M.C.M., M.P., A.S., M.T., K.V., J.G. and K.S. declare no conflict of interest. TRIAL REGISTRATION NUMBER: NCT01532284. TRIAL REGISTRATION DATE: 7 February 2012. DATE OF FIRST PATIENT’S ENROLMENT: 25 June 2012.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Verpoest W, Staessen C, Bossuyt PM, et al. Preimplantation genetic testing for aneuploidy by microarray analysis of polar bodies in advanced maternal age: a randomized clinical trial. Hum Reprod. 2018. PMID: 30085138. doi:10.1093/humrep/dey262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。